Global Cyclooxygenase 2 Inhibitor Market Growth (Status and Outlook) 2025-2031

According to this study, the global Cyclooxygenase 2 Inhibitor market size will reach US$ million by 2031.

COX inhibitors are mostly antipyretic and analgesic anti-inflammatory drugs, namely non-steroidal anti-inflammatory drugs (NSAIDs). COX-2 has extremely low activity in normal tissue cells, and can only be produced in large quantities when induced. It mediates pain, inflammation, and fever by promoting PG synthesis. In general, multiple adverse effects of non-steroidal anti-inflammatory drugs are believed to be related to the inhibition of COX-1. As a result, COX-2 selective inhibitors have emerged.

United States market for Cyclooxygenase 2 Inhibitor is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Cyclooxygenase 2 Inhibitor is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Cyclooxygenase 2 Inhibitor is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Cyclooxygenase 2 Inhibitor players cover Pfizer, Bayer, Novartis, Merck, Sabinsa, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LPI (LP Information)' newest research report, the “Cyclooxygenase 2 Inhibitor Industry Forecast” looks at past sales and reviews total world Cyclooxygenase 2 Inhibitor sales in 2024, providing a comprehensive analysis by region and market sector of projected Cyclooxygenase 2 Inhibitor sales for 2025 through 2031. With Cyclooxygenase 2 Inhibitor sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Cyclooxygenase 2 Inhibitor industry.

This Insight Report provides a comprehensive analysis of the global Cyclooxygenase 2 Inhibitor landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Cyclooxygenase 2 Inhibitor portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Cyclooxygenase 2 Inhibitor market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Cyclooxygenase 2 Inhibitor and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Cyclooxygenase 2 Inhibitor.

This report presents a comprehensive overview, market shares, and growth opportunities of Cyclooxygenase 2 Inhibitor market by product type, application, key players and key regions and countries.

Segmentation by Type:
Selective Cox 2 Inhibitor
Non-Selective Cox 2 Inhibitor

Segmentation by Application:
Hospital
Specialty Clinic
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Pfizer
Bayer
Novartis
Merck
Sabinsa
Cadila Pharmaceuticals
Mylan
Teva Pharmaceutical
Alembic Pharmaceutical
Aurobindo Pharma
Cipla
Torrent Pharmaceuticals

Please note: The report will take approximately 2 business days to prepare and deliver. Show more